Obesity-Related Digestive Diseases and Their Pathophysiology

키워드

참고문헌 (166)

1. Malik VS, "Global obesity: trends, risk factors and policy implications", Nat Rev Endocrinol, 9, pp.13~27 (2013)
2. Fujihara S, "Metabolic syndrome, obesity, and gastrointestinal cancer", Gastroenterol Res Pract, 2012, pp.483623~ (2012)
3. Nam SY, "Abdominal visceral adipose tissue volume is associated with increased risk of erosive esophagitis in men and women", Gastroenterology, 139, pp.1902~1911 (2010)
4. Nam SY, "Abdominal visceral adipose tissue predicts risk of colorectal adenoma in both sexes", Clin Gastroenterol Hepatol, 8, pp.443~450.e2 (2010)
5. Colicchio P, "Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy", Ann Nutr Metab, 49, pp.289~295 (2005)
6. Schmitz KH, "Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity", J Natl Cancer Inst, 105, pp.1344~1354 (2013)
7. LeRoith D, "Insulin-like growth factors and cancer", Ann Intern Med, 122, pp.54~59 (1995)
8. Watkins LF, "Characterization of the synergistic effect of insulin and transferrin and the regulation of their receptors on a human colon carcinoma cell line", Int J Cancer, 45, pp.372~375 (1990)
9. Kaaks R, "Energy balance and cancer: the role of insulin and insulin-like growth factor-I", Proc Nutr Soc, 60, pp.91~106 (2001)
10. Ma J, "Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3", J Natl Cancer Inst, 91, pp.620~625 (1999)
11. Giovannucci E, "A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women", Cancer Epidemiol Biomarkers Prev, 9, pp.345~349 (2000)
12. Ma J, "A prospective study of plasma C-peptide and colorectal cancer risk in men", J Natl Cancer Inst, 96, pp.546~553 (2004)
13. Schneider MB, "Prevention of pancreatic cancer induction in hamsters by metformin", Gastroenterology, 120, pp.1263~1270 (2001)
14. Sinnett-Smith J, "Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK", Biochem Biophys Res Commun, 430, pp.352~357 (2013)
15. Chiang GG, "Targeting the mTOR signaling network in cancer", Trends Mol Med, 13, pp.433~442 (2007)
16. Memmott RM, "Metformin prevents tobacco carcinogen: induced lung tumorigenesis", Cancer Prev Res (Phila), 3, pp.1066~1076 (2010)
17. Rabe K, "Adipokines and insulin resistance", Mol Med, 14, pp.741~751 (2008)
18. Krysiak R, "The role of adipokines in connective tissue diseases", Eur J Nutr, 51, pp.513~528 (2012)
19. Aaronson SA, "Growth factors and cancer", Science, 254, pp.1146~1153 (1991)
20. Tilg H, "Adipocytokines: mediators linking adipose tissue, inflammation and immunity", Nat Rev Immunol, 6, pp.772~783 (2006)
21. Feng H, "The role of leptin in obesity and the potential for leptin replacement therapy", Endocrine, 44, pp.33~39 (2013)
22. Fantuzzi G, "Leptin in the regulation of immunity, inflammation, and hematopoiesis", J Leukoc Biol, 68, pp.437~446 (2000)
23. Friedman JM, "Leptin and the regulation of body weight in mammals", Nature, 395, pp.763~770 (1998)
24. Amitani M, "The role of leptin in the control of insulin-glucose axis", Front Neurosci, 7, pp.51~ (2013)
25. Duggan C, "Association between markers of obesity and progression from Barrett’s esophagus to esophageal adenocarcinoma", Clin Gastroenterol Hepatol, 11, pp.934~943 (2013)
26. Endo H, "Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis", Gut, 60, pp.1363~1371 (2011)
27. Dallal CM, "Obesity-related hormones and endometrial cancer among postmenopausal women: a nested case-control study within the B~FIT cohort", Endocr Relat Cancer, 20, pp.151~160 (2013)
28. Watanabe N, "Increased levels of serum leptin are a risk factor for the recurrence of stage I", II hepatocellular carcinoma after curative treatment, 2011, pp.49, 153~158
29. Ogunwobi O, "Leptin stimulates proliferation and inhibits apoptosis in Barrett’s esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation", Endocrinology, 147, pp.4505~4516 (2006)
30. Aparicio T, "Leptin stimulates the proliferation of human colon cancer cells in vitro but does not promote the growth of colon cancer xenografts in nude mice or intestinal tumorigenesis in Apc(Min", +) mice, 2005, pp.54, 1136~1145
31. Chen C, "Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathway", Endocr Relat Cancer, 14, pp.513~529 (2007)
32. Fava G, "Leptin enhances cholangiocarcinoma cell growth", Cancer Res, 68, pp.6752~6761 (2008)
33. Wolf G, "New insights into thiol-mediated regulation of adiponectin secretion", Nutr Rev, 66, pp.642~645 (2008)
34. Ogunwobi OO, "Globular adiponectin, acting via adiponectin receptor-1, inhibits leptin-stimulated oesophageal adenocarcinoma cell proliferation", Mol Cell Endocrinol, 285, pp.43~50 (2008)
35. Kern PA, "Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression", Diabetes, 52, pp.1779~1785 (2003)
36. 남수연, "Circulating Inflammatory Cytokines Are Associated With the Risk of Barretths Esophagus in Western Persons", Journal of Neurogastroenterology and Motility (JNM), 20(4), pp.558~559 (2014), 대한소화기 기능성질환∙운동학회[DOI]
37. Obeid S, "Role of adiponectin and its receptors in cancer", Cancer Biol Med, 9, pp.213~220 (2012)
38. Scheid MP, "The role of adiponectin signaling in metabolic syndrome and cancer", Rev Endocr Metab Disord, 15, pp.157~167 (2014)
39. Kim AY, "Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation", Mol Endocrinol, 24, pp.1441~1452 (2010)
40. Wijesekara N, "Adiponectin-induced ERK and AKT phosphorylation protects against pancreatic beta cell apoptosis and increases insulin gene expression and secretion", J Biol Chem, 285, pp.33623~33631 (2010)
41. Nigro E, "Adiponectin affects lung epithelial A549 cell viability counteracting TNF alpha and IL-1beta toxicity through AdipoR1", Int J Biochem Cell Biol, 45, pp.1145~1153 (2013)
42. Sharma D, "Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis", Hepatology, 52, pp.1713~1722 (2010)
43. Yoneda K, "Expression of adiponectin receptors, AdipoR1 and AdipoR2, in normal colon epithelium and colon cancer tissue", Oncol Rep, 20, pp.479~483 (2008)
44. Ishikawa M, "Plasma adiponectin and gastric cancer", Clin Cancer Res, 11(2 Pt 1), pp.466~472 (2005)
45. Ishikawa M, "Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2", Cancer Sci, 98, pp.1120~1127 (2007)
46. Saxena NK, "Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma", Gastroenterology, 139, pp.1762~1773.e5 (2010)
47. Song M, "Plasma adiponectin and soluble leptin receptor and risk of colorectal cancer: a prospective study", Cancer Prev Res (Phila), 6, pp.875~885 (2013)
48. Meier U, "Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin", Clin Chem, 50, pp.1511~1525 (2004)
49. Kusminski CM, "Role of resistin in obesity, insulin resistance and type II diabetes", Clin Sci (Lond), 109, pp.243~256 (2005)
50. Wozniak SE, "Adipose tissue: the new endocrine organ? A review article", Dig Dis Sci, 54, pp.1847~1856 (2009)
51. Gonullu G, "Association between adiponectin, resistin, insulin resistance, and colorectal tumors", Int J Colorectal Dis, 25, pp.205~212 (2010)
52. Assiri AM, "Resistin, visfatin, adiponectin, and leptin: risk of breast cancer in pre- and postmenopausal Saudi females and their possible diagnostic and predictive implications as novel biomarkers", Dis Markers, 2015, pp.253519~ (2015)
53. Deshmukh SK, "Resistin and interleukin- 6 exhibit racially-disparate expression in breast cancer patients, display molecular association and promote growth and aggressiveness of tumor cells through STAT3 activation", Oncotarget, 6, pp.11231~11241 (2015)
54. Czekay RP, "PAI-1: an integrator of cell signaling and migration", Int J Cell Biol, 2011 (2011)
55. Sakakibara T, "PAI-1 expression levels in esophageal and colorectal cancers are closely correlated to those in corresponding normal tissues", Anticancer Res, 26, pp.4343~4347 (2006)
56. Placencio VR, "Plasminogen activator inhibitor-1 in cancer: rationale and insight for future therapeutic testing", Cancer Res, 75, pp.2969~2974 (2015)
57. Cheung KP, "Immunomodulation at epithelial sites by obesity and metabolic disease", Immunol Res, 52, pp.182~199 (2012)
58. Taylor KR, "Gammadelta T cells are reduced and rendered unresponsive by hyperglycemia and chronic TNFalpha in mouse models of obesity and metabolic disease", PLoS One, 5, pp.e11422~ (2010)
59. Ioan-Facsinay A, "Adipocytederived lipids modulate CD4+ T-cell function", Eur J Immunol, 43, pp.1578~1587 (2013)
60. Zhong J, "T-cell costimulation protects obesity-induced adipose inflammation and insulin resistance", Diabetes, 63, pp.1289~1302 (2014)
61. Schäffler A, "Role of adipose tissue as an inflammatory organ in human diseases", Endocr Rev, 27, pp.449~467 (2006)
62. Weisberg SP, "Obesity is associated with macrophage accumulation in adipose tissue", J Clin Invest, 112, pp.1796~1808 (2003)
63. Balkwill F, "Cancer and the chemokine network", Nat Rev Cancer, 4, pp.540~550 (2004)
64. Nam SY, "Obesity and weight gain as risk factors for erosive oesophagitis in men", Aliment Pharmacol Ther, 29, pp.1042~1052 (2009)
65. Jacobson BC, "Body-mass index and symptoms of gastroesophageal reflux in women", N Engl J Med, 354, pp.2340~2348 (2006)
66. Locke GR, , Am J Med, 106, pp.642~649 (1999)
67. El-Serag HB, "Obesity is an independent risk factor for GERD symptoms and erosive esophagitis", Am J Gastroenterol, 100, pp.1243~1250 (2005)
68. Chung SJ, "Metabolic syndrome and visceral obesity as risk factors for reflux oesophagitis: a cross-sectional case-control study of 7078 Koreans undergoing health check-ups", Gut, 57, pp.1360~1365 (2008)
69. Fraser-Moodie CA, "Weight loss has an independent beneficial effect on symptoms of gastro-oesophageal reflux in patients who are overweight", Scand J Gastroenterol, 34, pp.337~340 (1999)
70. Mathus-Vliegen LM, "Twenty-four-hour pH measurements in morbid obesity: effects of massive overweight, weight loss and gastric distension", Eur J Gastroenterol Hepatol, 8, pp.635~640 (1996)
71. Raftopoulos I, "Laparoscopic gastric bypass after antireflux surgery for the treatment of gastroesophageal reflux in morbidly obese patients: initial experience", Obes Surg, 14, pp.1373~1380 (2004)
72. Zainabadi K, "Laparoscopic revision of Nissen fundoplication to Roux-en-Y gastric bypass in morbidly obese patients", Surg Endosc, 22, pp.2737~2740 (2008)
73. Jones KB Jr, "Roux-en-Y gastric bypass: an effective antireflux procedure in the less than morbidly obese", Obes Surg, 8, pp.35~38 (1998)
74. Lagergren J, "Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma", N Engl J Med, 340, pp.825~831 (1999)
75. Souza RF, "Acid, bile, and CDX: the ABCs of making Barrett’s metaplasia", Am J Physiol Gastrointest Liver Physiol, 295, pp.G211~G218 (2008)
76. Hvid-Jensen F, "Incidence of adenocarcinoma among patients with Barrett’s esophagus", N Engl J Med, 365, pp.1375~1383 (2011)
77. Desai TK, "The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis", Gut, 61, pp.970~976 (2012)
78. Wani S, "Esophageal adenocarcinoma in Barrett’s esophagus after endoscopic ablative therapy: a meta-analysis and systematic review", Am J Gastroenterol, 104, pp.502~513 (2009)
79. Rubenstein JH, "Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux", Aliment Pharmacol Ther, 32, pp.1222~1227 (2010)
80. Hoyo C, "Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium", Int J Epidemiol, 41, pp.1706~1718 (2012)
81. Singh S, "Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis", Clin Gastroenterol Hepatol, 11, pp.1399~1412.e7 (2013)
82. Thrift AP, "Obesity and risk of esophageal adenocarcinoma and Barrett’s esophagus: a Mendelian randomization study", J Natl Cancer Inst, 106, pp.dju252~ (2014)
83. Derakhshan MH, "Mechanism of association between BMI and dysfunction of the gastro-oesophageal barrier in patients with normal endoscopy", Gut, 61, pp.337~343 (2012)
84. Pandolfino JE, "Obesity: a challenge to esophagogastric junction integrity", Gastroenterology, 130, pp.639~649 (2006)
85. Garcia JM, "Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett’s esophagus: a case-control study", Clin Gastroenterol Hepatol, 12, pp.229~238.e3 (2014)
86. Drahos J, "Metabolic syndrome increases risk of Barrett esophagus in the absence of gastroesophageal reflux: an analysis of SEER-Medicare data", J Clin Gastroenterol, 49, pp.282~288 (2015)
87. Lindkvist B, "Metabolic risk factors for esophageal squamous cell carcinoma and adenocarcinoma: a prospective study of 580,000 subjects within the Me-Can project", BMC Cancer, 14, pp.103~ (2014)
88. Greer KB, "Association of insulin and insulin-like growth factors with Barrett’s oesophagus", Gut, 61, pp.665~672 (2012)
89. McElholm AR, "A populationbased study of IGF axis polymorphisms and the esophageal inflammation, metaplasia, adenocarcinoma sequence", Gastroenterology, 139, pp.204~212 (2010)
90. MacDonald K, "A polymorphic variant of the insulin-like growth factor type I receptor gene modifies risk of obesity for esophageal adenocarcinoma", Cancer Epidemiol, 33, pp.37~40 (2009)
91. Siahpush SH, "Longitudinal study of insulin-like growth factor, insulin-like growth factor binding protein-3, and their polymorphisms: risk of neoplastic progression in Barrett’s esophagus", Cancer Epidemiol Biomarkers Prev, 16, pp.2387~2395 (2007)
92. Thompson OM, "Serum leptin and adiponectin levels and risk of Barrett’s esophagus and intestinal metaplasia of the gastroesophageal junction", Obesity (Silver Spring), 18, pp.2204~2211 (2010)
93. Kendall BJ, "Leptin and the risk of Barrett’s oesophagus", Gut, 57, pp.448~454 (2008)
94. Rubenstein JH, "Association of adiponectin multimers with Barrett’s oesophagus", Gut, 58, pp.1583~1589 (2009)
95. Rubenstein JH, "A pilot study of the association of low plasma adiponectin and Barrett’s esophagus", Am J Gastroenterol, 103, pp.1358~1364 (2008)
96. Rubenstein JH, "Associations of diabetes mellitus, insulin, leptin, and ghrelin with gastroesophageal reflux and Barrett’s esophagus", Gastroenterology, 145, pp.1237~1244.e5 (2013)
97. Whiteman DC, "Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus", Gut, 57, pp.173~180 (2008)
98. Murphy TK, "Body mass index and colon cancer mortality in a large prospective study", Am J Epidemiol, 152, pp.847~854 (2000)
99. Calle EE, "Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults", N Engl J Med, 348, pp.1625~1638 (2003)
100. Kim Y, "An association between colonic adenoma and abdominal obesity: a cross-sectional study", BMC Gastroenterol, 9, pp.4~ (2009)
101. Kim JH, "Is metabolic syndrome a risk factor for colorectal adenoma?", Cancer Epidemiol Biomarkers Prev, 16, pp.1543~1546 (2007)
102. Giovannucci E, "Insulin, insulin-like growth factors and colon cancer: a review of the evidence", J Nutr, 131(11 Suppl), pp.3109S~3320S (2001)
103. Hayashi T, "Visceral adiposity, not abdominal subcutaneous fat area, is associated with an increase in future insulin resistance in Japanese Americans", Diabetes, 57, pp.1269~1275 (2008)
104. Hayashi T, "Visceral adiposity is an independent predictor of incident hypertension in Japanese Americans", Ann Intern Med, 140, pp.992~1000 (2004)
105. Oh TH, "Visceral obesity as a risk factor for colorectal neoplasm", J Gastroenterol Hepatol, 23, pp.411~417 (2008)
106. Sass DA, "Relationship of visceral adipose tissue to recurrence of adenomatous polyps", Am J Gastroenterol, 99, pp.687~693 (2004)
107. Erarslan E, "Association of visceral fat accumulation and adiponectin levels with colorectal neoplasia", Dig Dis Sci, 54, pp.862~868 (2009)
108. Frezza EE, "Influence of obesity on the risk of developing colon cancer", Gut, 55, pp.285~291 (2006)
109. Ahmed RL, "The metabolic syndrome and risk of incident colorectal cancer", Cancer, 107, pp.28~36 (2006)
110. Wajchenberg BL, "Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome", Endocr Rev, 21, pp.697~738 (2000)
111. Mizoue T, "Alcohol drinking and colorectal cancer in Japanese: a pooled analysis of results from five cohort studies", Am J Epidemiol, 167, pp.1397~1406 (2008)
112. Burton A, "Young adulthood body mass index and risk of cancer in later adulthood: historical cohort study", Cancer Causes Control, 21, pp.2069~2077 (2010)
113. Harriss DJ, "Lifestyle factors and colorectal cancer risk (1): systematic review and meta-analysis of associations with body mass index", Colorectal Dis, 11, pp.547~563 (2009)
114. Dai Z, "Obesity and colorectal cancer risk: a metaanalysis of cohort studies", World J Gastroenterol, 13, pp.4199~4206 (2007)
115. Guh DP, "The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis", BMC Public Health, 9, pp.88~ (2009)
116. Moghaddam AA, "Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events", Cancer Epidemiol Biomarkers Prev, 16, pp.2533~2547 (2007)
117. Matsuo K, "Association between body mass index and the colorectal cancer risk in Japan: pooled analysis of population-based cohort studies in Japan", Ann Oncol, 23, pp.479~490 (2012)
118. Bassett JK, "Body size, weight change, and risk of colon cancer", Cancer Epidemiol Biomarkers Prev, 19, pp.2978~2986 (2010)
119. Laake I, "A prospective study of body mass index, weight change, and risk of cancer in the proximal and distal colon", Cancer Epidemiol Biomarkers Prev, 19, pp.1511~1522 (2010)
120. Chen J, "Estrogen in obesity-associated colon cancer: friend or foe? Protecting postmenopausal women but promoting late-stage colon cancer", Cancer Causes Control, 23, pp.1767~1773 (2012)
121. Calle EE, "Obesity and cancer", BMJ, 335, pp.1107~1108 (2007)
122. Angulo P, "Non-alcoholic fatty liver disease", J Gastroenterol Hepatol, 17(Suppl), pp.S186~S190 (2002)
123. Dixon JB, "Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese", Gastroenterology, 121, pp.91~100 (2001)
124. Gholam PM, "Liver pathology in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery", Obes Surg, 12, pp.49~51 (2002)
125. Beymer C, "Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery", Arch Surg, 138, pp.1240~1244 (2003)
126. Bugianesi E, "Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms", Diabetologia, 48, pp.634~642 (2005)
127. Liangpunsakul S, "Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III)", Am J Med Sci, 329, pp.111~116 (2005)
128. Marchesini G, "Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome", Hepatology, 37, pp.917~923 (2003)
129. Papandreou D, "Update on non-alcoholic fatty liver disease in children", Clin Nutr, 26, pp.409~415 (2007)
130. Day CP, "Steatohepatitis: a tale of two “hits”?", Gastroenterology, 114, pp.842~845 (1998)
131. Gomaa AI, "Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis", World J Gastroenterol, 14, pp.4300~4308 (2008)
132. Parkin DM, "Global cancer statistics in the year 2000", Lancet Oncol, 2, pp.533~543 (2001)
133. El-Serag HB, "Rising incidence of hepatocellular carcinoma in the United States", N Engl J Med, 340, pp.745~750 (1999)
134. Bosch FX, "Primary liver cancer: worldwide incidence and trends", Gastroenterology, 127(5 Suppl 1), pp.S5~S16 (2004)
135. Ohata K, "Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection", Cancer, 97, pp.3036~3043 (2003)
136. Ohki T, "Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients", Clin Gastroenterol Hepatol, 6, pp.459~464 (2008)
137. Konishi I, "Diabetes pattern on the 75 g oral glucose tolerance test is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus", Liver Int, 29, pp.1194~1201 (2009)
138. Caldwell S, "The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology", J Gastroenterol, 44(Suppl 19), pp.96~101 (2009)
139. El-Serag HB, "Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma", Gastroenterology, 126, pp.460~468 (2004)
140. Lai MS, "Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection", Hepatology, 43, pp.1295~1302 (2006)
141. Bugianesi E, "Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma", Gastroenterology, 123, pp.134~140 (2002)
142. Siegel AB, "Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link", Cancer, 115, pp.5651~5661 (2009)
143. Chen HP, "Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: populationbased and in vitro studies", Gut, 62, pp.606~615 (2013)
144. Wang F, "Association between obesity and gallbladder cancer", Front Biosci (Landmark Ed), 17, pp.2550~2558 (2012)
145. Jing W, "Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis", Eur J Cancer Prev, 21, pp.24~31 (2012)
146. Zhang LF, "Diabetes mellitus and increased risk of extrahepatic cholangiocarcinoma: a meta-analysis", Hepatogastroenterology, 60, pp.684~687 (2013)
147. Nöthlings U, "Body mass index and physical activity as risk factors for pancreatic cancer: the multiethnic cohort study", Cancer Causes Control, 18, pp.165~175 (2007)
148. Michaud DS, "Physical activity, obesity, height, and the risk of pancreatic cancer", JAMA, 286, pp.921~929 (2001)
149. Li D, "Body mass index and risk, age of onset, and survival in patients with pancreatic cancer", JAMA, 301, pp.2553~2562 (2009)
150. McWilliams RR, "Obesity adversely affects survival in pancreatic cancer patients", Cancer, 116, pp.5054~5062 (2010)
151. Yang P, "Overweight, obesity and gastric cancer risk: results from a meta-analysis of cohort studies", Eur J Cancer, 45, pp.2867~2873 (2009)
152. Chen Y, "Body mass index and risk of gastric cancer: a meta-analysis of a population with more than ten million from 24 prospective studies", Cancer Epidemiol Biomarkers Prev, 22, pp.1395~1408 (2013)
153. Eslick GD, "Gastrointestinal symptoms and obesity: a meta-analysis", Obes Rev, 13, pp.469~479 (2012)
154. Eslick GD, "Prevalence and relationship between gastrointestinal symptoms among individuals of different body mass index: a population-based study", Obes Res Clin Pract, 10, pp.143~150 (2016)
155. Breckan RK, "Prevalence, comorbidity, and risk factors for functional bowel symptoms: a population-based survey in Northern Norway", Scand J Gastroenterol, 47, pp.1274~1282 (2012)
156. 박혜순, "Effect of Weight Reduction on Metabolic Syndrome in Korean Obese Patients", Journal of Korean Medical Science, 19(2), pp.202~208 (2004), 대한의학회
157. Busetto L, "Visceral obesity and the metabolic syndrome: effects of weight loss", Nutr Metab Cardiovasc Dis, 11, pp.195~204 (2001)
158. Bower G, "Bariatric surgery and nonalcoholic fatty liver disease: a systematic review of liver biochemistry and histology", Obes Surg, 25, pp.2280~2289 (2015)
159. Maestro A, "Does bariatric surgery reduce cancer risk? A review of the literature", Endocrinol Nutr, 62, pp.138~143 (2015)
160. Arterburn DE, "Bariatric surgery for obesity and metabolic conditions in adults", BMJ, 349, pp.g961~ (2014)
161. Adams TD, "All-cause and cause-specific mortality associated with bariatric surgery: a review", Curr Atheroscler Rep, 17, pp.74~ (2015)
162. Meyerhardt JA, "Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803", J Clin Oncol, 26, pp.4109~4115 (2008)
163. Sinicrope FA, "Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy", Cancer, 119, pp.1528~1536 (2013)
164. Chan DS, "Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies", Ann Oncol, 25, pp.1901~1914 (2014)
165. Goodwin PJ, "Randomized trial of a telephone- based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial", J Clin Oncol, 32, pp.2231~2239 (2014)
166. Rock CL, "Results of the exercise and nutrition to enhance recovery and good health for you (ENERGY) trial: a behavioral weight loss intervention in overweight or obese breast cancer survivors", J Clin Oncol, 33, pp.3169~3176 (2015)

관련 논문AI추천